Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C13H21N5O2 |
Molecular Weight | 279.3381 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](CCC3=NN=NN3)C[C@]1([H])C[C@H](NC2)C(O)=O
InChI
InChIKey=ZXFRFPSZAKNPQQ-YTWAJWBKSA-N
InChI=1S/C13H21N5O2/c19-13(20)11-6-10-5-8(1-3-9(10)7-14-11)2-4-12-15-17-18-16-12/h8-11,14H,1-7H2,(H,19,20)(H,15,16,17,18)/t8-,9+,10-,11+/m1/s1
Molecular Formula | C13H21N5O2 |
Molecular Weight | 279.3381 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Tezampanel, also known as LY 293558 and NGX-424, is a drug originally developed by Eli Lilly, which is a competitive antagonist of the AMPA and kainate subtypes of the ionotropic glutamate receptor family. Tezampanel was in phase II clinical trial for treatment migraine, but this study was discontinued. Also this drug has several others potential pharmacological actions, one of them is anxiety disorders
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23042954
Curator's Comment: Known to be CNS penetrant in rat. Human data not available
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2109241 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8609884 |
|||
Target ID: CHEMBL2096670 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7760975 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18433 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23042954 |
15 mg/kg single, intramuscular dose: 15 mg/kg route of administration: Intramuscular experiment type: SINGLE co-administered: |
TEZAMPANEL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9396 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23042954 |
15 mg/kg single, intramuscular dose: 15 mg/kg route of administration: Intramuscular experiment type: SINGLE co-administered: |
TEZAMPANEL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23042954 |
15 mg/kg single, intramuscular dose: 15 mg/kg route of administration: Intramuscular experiment type: SINGLE co-administered: |
TEZAMPANEL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Differential involvement of NMDA, AMPA/kainate, and dopamine receptors in the nucleus accumbens core in the acquisition and performance of pavlovian approach behavior. | 2001 Dec 1 |
|
Amygdala regulation of nucleus accumbens dopamine output is governed by the prefrontal cortex. | 2001 Jan 15 |
|
LY-293558. Eli Lilly & Co. | 2001 Sep |
|
Glutamate receptors in the rat medial prefrontal cortex regulate set-shifting ability. | 2003 Aug |
|
Distinct contributions of glutamate receptor subtypes to cognitive set-shifting abilities in the rat. | 2003 Nov |
|
Histaminergic modulation of excitatory synaptic transmission in the rat basolateral amygdala. | 2005 |
|
Gateways to clinical trials. | 2008 Oct |
|
Fractionating spatial memory with glutamate receptor subunit-knockout mice. | 2009 Dec |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00567086
Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16470401
LY293558 (Tezampanel) had a rank order of potency of GLU(K5) > or = GLU(K5/6) approximately GLU(A2i) approximately GLU(K2/5) approximately GLU(A1i) approximately GLU(A2o) approximately GLU(A3i) approximately GLU(A1o) > or = GLU(A3o) > or = GLU(A4i) approximately GLU(A4o) and >100 microM affinity for rat cortical GABA(A) receptors. Comparison of the blockade of AMPA- vs N-methyl-D-aspartate (NMDA)-induced inward currents demonstrated that LY293558 was five-fold more potent as an antagonist at AMPA vs NMDA receptors in vitro.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:01:12 GMT 2023
by
admin
on
Fri Dec 15 16:01:12 GMT 2023
|
Record UNII |
GA36S2O9C2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47795
Created by
admin on Fri Dec 15 16:01:12 GMT 2023 , Edited by admin on Fri Dec 15 16:01:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
GA36S2O9C2
Created by
admin on Fri Dec 15 16:01:12 GMT 2023 , Edited by admin on Fri Dec 15 16:01:12 GMT 2023
|
PRIMARY | |||
|
8743
Created by
admin on Fri Dec 15 16:01:12 GMT 2023 , Edited by admin on Fri Dec 15 16:01:12 GMT 2023
|
PRIMARY | |||
|
C80379
Created by
admin on Fri Dec 15 16:01:12 GMT 2023 , Edited by admin on Fri Dec 15 16:01:12 GMT 2023
|
PRIMARY | |||
|
154652-83-2
Created by
admin on Fri Dec 15 16:01:12 GMT 2023 , Edited by admin on Fri Dec 15 16:01:12 GMT 2023
|
PRIMARY | |||
|
TEZAMPANEL
Created by
admin on Fri Dec 15 16:01:12 GMT 2023 , Edited by admin on Fri Dec 15 16:01:12 GMT 2023
|
PRIMARY | |||
|
127894
Created by
admin on Fri Dec 15 16:01:12 GMT 2023 , Edited by admin on Fri Dec 15 16:01:12 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |